Search Results

You are looking at 1 - 10 of 15 items for :

  • "cabergoline" x
Clear All
Open access

Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes and Antoine Tabarin

, pegvisomant (PEG), is a second-line treatment which normalizes IGF-1 plasma levels in 60–70% ( 5 ) of patients in follow-up registries and up to 97% in single-center series ( 6 ). The dopamine D2-receptor agonist, cabergoline, is an alternative to 1 GSSA

Open access

Shruti Khare, Anurag R Lila, Hiren Patt, Chaitanya Yerawar, Manjunath Goroshi, Tushar Bandgar and Nalini S Shah

cabergoline is the first line therapy for macroprolactinoma. Cabergoline is started at dose of 0.25 mg in the first week and then increased to 0.5 mg/week in the second week. Further dose is escalated (if need be) by 1 mg/week, at 2 monthly intervals. Before

Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp and Gunter Karl Stalla

.09.1998–01.03.1999; 24.06.1999–03.12.2001) with interruptions and in combination with cabergoline (02.10.1998–07.10.1999; 03.12.2001-ongoing). Interestingly, the psychiatric symptoms were similar under all dopamine agonists administered with the ICD codes including

Open access

Lijin Ji, Na Yi, Qi Zhang, Shuo Zhang, Xiaoxia Liu, Hongli Shi and Bin Lu

effects. Tumor mass effects can cause visual field defects, decreased vision, headaches and can even be life threatening. Drug therapy is recommended for prolactinoma, and the dopamine receptor agonists (DAs) bromocriptine and cabergoline are commonly

Open access

Sarah Byberg, Jesper Futtrup, Mikkel Andreassen and Jesper Krogh

hyperprolactinemia OR prolactinoma) AND (dopamine agonist OR dostinex OR cabergoline OR bromocriptine). The search was restricted to titles. One investigator (SB) conducted the main search. Based on title and abstract, obviously irrelevant titles were removed and

Open access

Julie M Silverstein

-acting dopamine agonists such as carbergoline (1) . Cabergoline is recommended in patients with mild disease, defined as IGF1 levels less than two times the upper limit of normal, and in cases of co-secretion with prolactin (1, 15) . In clinical studies, ∼30% of

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

In this patient, macroprolactinoma was diagnosed when she was 42 years old and trans-sphenoidal surgery was performed after few months of ineffective high-dose cabergoline treatment. At the age of 55 years, serum PRL concentrations remarkably

Open access

Mikkel Andreassen, Anders Juul, Ulla Feldt-Rasmussen and Niels Jørgensen

– 2037 . ( https://doi.org/10.1093/humrep/dev158 ) 10.1093/humrep/dev158 8 De Rosa M Colao A Di SA Ferone D Landi ML Zarrilli S Paesano L Merola B Lombardi G. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

adenoma was identified ( Fig. 3 ). She was diagnosed with a prolactinoma; cabergoline (0.5 mg/week) was started and normalized the prolactin, but the tumor was unchanged on MRI 12 months later. The patient was abroad without endocrine follow-up for more

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

limit of normal in association with a macroadenoma on MRI. Lack of hormonal control (DA resistance) was defined as per Molitch ( 17 ) as a failure to achieve normalization of serum prolactin at the highest labeled dose of cabergoline (2 mg